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Type II topoisomerases perform essential roles in DNA replication, chromosome segregation, and recombination and are
important antibacterial and anticancer targets [1]. Bacterial drug resistance is a growing and now widely recognised threat
and the limited number of new antibacterials developed in the recent years is a matter of serious concern. One of the
approaches to combat this growing threat is to investigate deeply the mechanisms of action of currently available
antibacterials, as well as studying the way that bacteria are developing drug resistance and may potentially in the future
develop drug resistance to known drugs. This knowledge will in turn be used in the rational drug design and the general
development of the appropriate molecular frameworks for combating bacterial infections, while at the same time keeping the
negative side effects of the drugs to an acceptable minimum. This is especially important when both bacteria and humans
share similar drug targets, such as is the case for type II topoisomerases (in humans topo IIα and topo IIβ are targeted by
anti-cancer drugs i.e. doxorubicin and etoposide), whereas in prokaryotes Gyrase and topoisomerase IV (topoIV) may be
targeted by quinolones and quinazolinediones. 
Type II topoisomerases which are involved in regulation of the DNA supercoiling in both bacteria (gyrase) and eukaryotes
and also in decatenation of bacterial daughter chromosomes during cell division (topo IV). Type II topoisomerases perform
their biological action by binding double stranded DNA (called G-segment or Gate-DNA), temporarily cleaving it and passing
another double stranded DNA (called T-segment) in the ATP-assisted process via the cleavage region thus changing the
linking number in steps of ±2. After that the G-segment is resealed and released. Quinolones, doxorubicin and etoposide
are found to be able to disrupt this process ultimately resulting in the cell death (hence their anti-bacterial or anti-cancer
action). Here we present our studies on the topo II catalytic cycle and the protein-DNA-drug interactions which are involved
in the action of clinically used and newly developed quinolone antibacterials [2-3].
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